Production (Stage)
Lipella Pharmaceuticals Inc.
LIPO
$2.99
-$0.10-3.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 129.40K | 173.70K | 80.40K | 136.40K | 145.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 129.40K | 173.70K | 80.40K | 136.40K | 145.90K |
| Cost of Revenue | 993.50K | 1.06M | 1.05M | 661.60K | 842.60K |
| Gross Profit | -864.10K | -888.70K | -966.30K | -525.10K | -696.70K |
| SG&A Expenses | 463.70K | 562.60K | 493.10K | 427.10K | 520.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.46M | 1.63M | 1.54M | 1.09M | 1.36M |
| Operating Income | -1.33M | -1.45M | -1.46M | -952.20K | -1.22M |
| Income Before Tax | -1.31M | -1.44M | -1.44M | -938.10K | -1.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.31M | -1.44M | -1.44M | -938.10K | -1.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.31M | -1.44M | -1.44M | -938.10K | -1.19M |
| EBIT | -1.33M | -1.45M | -1.46M | -952.20K | -1.22M |
| EBITDA | -1.33M | -1.45M | -1.46M | -950.80K | -1.22M |
| EPS Basic | -0.64 | -1.19 | -1.29 | -0.99 | -1.31 |
| Normalized Basic EPS | -0.40 | -0.74 | -0.81 | -0.62 | -0.82 |
| EPS Diluted | -0.64 | -1.19 | -1.29 | -0.99 | -1.31 |
| Normalized Diluted EPS | -0.40 | -0.74 | -0.81 | -0.62 | -0.82 |
| Average Basic Shares Outstanding | 2.06M | 1.21M | 1.12M | 950.70K | 911.50K |
| Average Diluted Shares Outstanding | 2.06M | 1.21M | 1.12M | 950.70K | 911.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |